drugset
drugset / Trial / NCT05021536

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

NCT05021536 ↗

Phase 3 Active not recruiting 664 enrolled Amylyx Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

Timeline

Start
2021-10-28
Primary completion
2024-01-19
Completion
2026-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AMX0035 Unknown — —

Indications

amyotrophic lateral sclerosis